Carmen Aguilar obtained her degree in Biotechnology from the Autonomous University of Barcelona (UAB) in 2008, after which, funded by a Leonardo da Vinci grant, she spent several months at the European Molecular Biology Laboratory (EMBL) in Heidelberg (Germany).
In July 2009, she commenced studies for her PhD in Structural Biology at the EMBL headquarters in Grenoble (France), under the supervision of Dr Daniel Panne. In January 2015, she joined the Alternative Energies and Atomic Energy Commission (CEA) in Grenoble as a post-doctoral researcher, where she was supervised by Dr Marie-Odile Fauvarque and worked closely with Dr Winfried Weissenhorn. In October 2017 she joined IrsiCaixa’s Cell Virology and Immunology (VIC) group as a post-doctoral researcher under Dr Julià Blanco. She is currently working on the development of a new vaccination against HIV and on other infectious diseases.